Tackling the problems of tumour chemotherapy by optimal drug scheduling.

J Clin Diagn Res

Associate Professor, Department of Pharmacology and Therapeutics, Dr SMCSI Medical College, Karakonam, India .

Published: July 2013

Introduction: There are various strategies for overcoming the major pitfalls of cancer chemotherapy, such as toxicity and drug resistance. The scientific computing of drug scheduling by optimisation before drug administration is one among them. In a majority of these strategies, the pharmacodynamic variations are given more importance than the pharmacokinetic variations. This study was meant to analyse the importance of the pharmacokinetic parameters (φ) of the individual patients in cancer chemotherapy scheduling, along with the pharmacodynamic factors.

Methods: A mathematical model is developed and it is implemented in the open source OCTAVE GNU LINUX. Optimisation is done by using an optimization tool in OCTAVE. The present study was aimed at evaluating the daily drug dosaging and cyclic chemotherapy which are commonly practised in the chemotherapy scheduling. Four cases were analyzed with and without considering the pharmacokinetic parameters. The optimal therapy was meant to reduce the number of cancer cells to a minimum at the end of the therapy and to minimise the emergence of resistant cancer cells. Since the dose was within tolerable limits, the toxic effects could also be minimised.

Results: Even with the consideration of a 1 per cent effect (φ), the maximum possible dose and the performance index were increased in the daily scheduling. But in the cyclic therapy, even though the maximum tolerated dose or the performance index was not altered, the cumulative toxicity was greatly reduced.

Conclusion: Daily scheduling and cyclic chemotherapy can be applied alternatively more effectively, by considering the interindividual variations in the pharmacokinetic effect (φ).

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3749646PMC
http://dx.doi.org/10.7860/JCDR/2013/6223.3144DOI Listing

Publication Analysis

Top Keywords

drug scheduling
8
cancer chemotherapy
8
variations pharmacokinetic
8
pharmacokinetic parameters
8
chemotherapy scheduling
8
cyclic chemotherapy
8
cancer cells
8
dose performance
8
daily scheduling
8
scheduling cyclic
8

Similar Publications

Introduction: Giant omphalocele poses a conflict between eviscerated content and abdominal capacity, with associated risks such as compartment syndrome or cardiovascular compromise.

Clinical Case: We present the case of a prenatally diagnosed hepato-omphalocele, without associated abnormalities. At week 37, botulinum toxin was injected in the right hemiabdomen under fetal and maternal sedation.

View Article and Find Full Text PDF

Infectious animal diseases represent a major constraint to livestock productivity, food security and wellbeing in many developing countries. To mitigate these impacts, farmers frequently use antimicrobials without professional advice, potentially yielding drug residues in livestock products and the food chain, as well as resistant antimicrobial genes. Recent studies identified Contagious Bovine Pleuropneumonia (CBPP) and Peste des Petits Ruminants (PPR) as the diseases most negatively affecting ruminant livestock productivity and farmers' wellbeing in Ghana.

View Article and Find Full Text PDF

Patient centered medication treatment for opioid use disorder in rural Vermont: a qualitative study.

Addict Sci Clin Pract

January 2025

Center for Technology and Behavioral Health, Geisel School of Medicine, Dartmouth College, Lebanon, NH, 03766, USA.

Background: Opioid-related fatal overdoses are occurring at historically high levels and increasing each year. Accessible social and financial support are imperative to the initiation and success of treatment for Opioid Use Disorder (OUD). Medications for Opioid Use Disorder (MOUD) offer effective treatment but there are many more people with untreated OUD than receiving evidence-based medication.

View Article and Find Full Text PDF

The development of new and improved antiretroviral therapies that allow for alternative dosing schedules is needed for people living with HIV-1. Islatravir is a deoxyadenosine analog in development for the treatment of HIV-1 that suppresses HIV-1 replication via multiple mechanisms of action, including reverse transcriptase translocation inhibition and delayed chain termination. Islatravir is differentiated from other HIV-1 antiretrovirals by its high potency, long , broad tissue distribution, and favorable drug resistance profile.

View Article and Find Full Text PDF

Medication related osteonecrosis (MRONJ) in the management of CTIBL in breast and prostate cancer patients. Joint report by SIPMO AND SIOMMMS.

J Bone Oncol

February 2025

Unit of Oral Medicine and Dentistry for Frail Patients, Department of Rehabilitation, Fragility, and Continuity of Care, Regional Center for Research and Care of MRONJ, University Hospital Palermo, Palermo, PA, Italy.

Background: Low-doses of bone modifying agents (LD-BMAs) compared to those used to treat bone metastases are used in breast or prostate cancer patients on adjuvant endocrine therapy to prevent Cancer Treatment Induced Bone Loss (CTIBL). Their use is associated with an increased risk of developing Medication-Related Osteonecrosis of the Jaw (MRONJ). However, there is not clarity about strategies aimed to minimize the MRONJ risk in cancer patients at different conditions as low- vs high-doses of BMA.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!